A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer

被引：0
|
作者：
Yoshino, T. [1 ]
Siena, S. [2 ]
Dalal, R. [3 ]
Okuda, Y. [4 ]
Yamamoto, E. [5 ]
Grothey, A. [6 ]
机构：
[1] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Univ Milan, Niguarda Canc Ctr, Milan, Italy
[3] Daiichi Sankyo Inc, Med, Basking Ridge, NJ USA
[4] Daiichi Sankyo Co Ltd, Biostat & Data Management Dept, Chuo Ku, Tokyo, Japan
[5] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan
[6] Mayo Clin, Canc Ctr, Dept Med Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146TiP
引用
收藏
页码：45 / 45
页数：1
相关论文
共 50 条
  • [21] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer
    Tsurutani, J.
    Park, H.
    Doi, T.
    Modi, S.
    Takahashi, S.
    Nakagawa, K.
    Krop, I.
    Waqar, S.
    Yoh, K.
    Li, B.
    Taira, S.
    Jikoh, T.
    Singh, J.
    Sugihara, M.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S324 - S324
  • [23] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Planchard, D.
    Li, B. T.
    Murakami, H.
    Shiga, R.
    Lee, C. C.
    Wang, K.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Fuchs, Charles S.
    Shahidi, Javad
    Mathew, Lijoy
    Qin, Amy
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs TDM1 for HER2-positive breast cancer
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
    Tamura, Kenji
    Tsurutani, Junji
    Takahashi, Shunji
    Iwata, Hiroji
    Krop, Ian E.
    Redfern, Charles
    Sagara, Yasuaki
    Doi, Toshihiko
    Park, Haeseong
    Murthy, Rashmi K.
    Redman, Rebecca A.
    Jikoh, Takahiro
    Lee, Caleb
    Sugihara, Masahiro
    Shahidi, Javad
    Yver, Antoine
    Modi, Shanu
    LANCET ONCOLOGY, 2019, 20 (06): : 816 - 826
  • [27] Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [28] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
    Takayuki Yoshino
    Maria Di Bartolomeo
    Kanwal Raghav
    Toshiki Masuishi
    Fotios Loupakis
    Hisato Kawakami
    Kensei Yamaguchi
    Tomohiro Nishina
    Zev Wainberg
    Elena Elez
    Javier Rodriguez
    Marwan Fakih
    Fortunato Ciardiello
    Kapil Saxena
    Kojiro Kobayashi
    Emarjola Bako
    Yasuyuki Okuda
    Gerold Meinhardt
    Axel Grothey
    Salvatore Siena
    Nature Communications, 14
  • [29] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
    Ohba, Akihiro
    Morizane, Chigusa
    Kawamoto, Yasuyuki
    Komatsu, Yoshito
    Ueno, Makoto
    Kobayashi, Satoshi
    Ikeda, Masafumi
    Sasaki, Mitsuhito
    Furuse, Junji
    Okano, Naohiro
    Hiraoka, Nobuyoshi
    Yoshida, Hiroshi
    Kuchiba, Aya
    Sadachi, Ryo
    Nakamura, Kenichi
    Matsui, Naoko
    Nakamura, Yoshiaki
    Okamoto, Wataru
    Yoshino, Takayuki
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
    Hamilton, Erika
    Shapiro, Charles L.
    Petrylak, Daniel
    Boni, Valentina
    Martin, Miguel
    Del Conte, Gianluca
    Cortes, Javier
    Agarwal, Laila
    Arkenau, Hendrik-Tobias
    Tan, Antoinette R.
    Debruyne, Philip
    Minchom, Anna
    Rutten, Annemie
    Valdes-Albini, Frances
    Yu, Evan Y.
    Augustine, Bincy
    D'Amelio, Anthony, Jr.
    Barrios, Daniel
    Hurvitz, Sara A.
    CANCER RESEARCH, 2021, 81 (04)
12345